Richard Keenan, Project Director
Richard Keenan, Ph.D., has over 20 years of experience in medicinal chemistry research, contributing directly to the discovery of numerous clinical development compounds from a variety of therapeutic areas, including 2 marketed drugs: the Angiotensin Receptor blocker Teveten and the TPO receptor agonist Promacta. At GlaxoSmithKline, he served as VP of Drug Discovery and was one of the founding members of the Center of Excellence for External Drug Discovery (CEEDD).
Glen Gaughan, Project Manager Glen Gaughan, Ph.D., was a drug discovery scientist with Bristol-Myers Squibb for almost 20 years. In roles ranging from Principal Investigator to Group Leader, he contributed to programs searching for new medications for pain, obesity, sleep disorders and depression, and developed new contrast agents for MRI (ProHance). He subsequently worked for 12 years in the small biotech and consulting domains as a Director of Business Development and as CEO-in-Residence at BioEnterprise. He has been an active participant in the Harrington project since its inception, supporting both the non-profit Harrington Discovery Institute and BioMotiv. He holds a Ph.D. from the University of Oregon, an MBA from Case Western Reserve University, and a B.A. from Dartmouth College.